Brain47Brain47Join Brain47
0A5J

Dermapharm Holding SE

Healthcare · EUR · XETRA

DMPT212

Price

€49

+0.77%

Cap

€2.50B

Earnings

—

30d Trend

+6.5%

0A5J
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityModerate

39% annualised over 90 days

BRAIN47 SIGNAL

0
STRONG
Risk Level51
Quality56
Momentum88
Technical57
Fundamentals66

Raw weighted: 65×Macro 0.99 (−1%)=64

RISK

51/100
90d Volatility
38.9%High
ATR %
2.9%Normal
Max Drawdown (1Y)
-11.8%Resilient

QUALITY

56/100
ROE (avg)
20.2%Excellent
Piotroski F-Score
6/9Average
Debt/Equity
1.52High leverage
Margin Stability
CV 23.8%Volatile
Accruals
-2.2%Cash earnings
Interest Coverage
4.2xAdequate

MOMENTUM

88/100
12-1M Momentum
+35.5%Strong uptrend
6-1M Momentum
+22.7%Positive
1M Return
+6.3%Strong recent gains

TECHNICAL

57/100
RSI (14)
56.3Neutral
Price vs SMA200
+28.3%Bullish trend
MACD
-0.16Bearish momentum
Bollinger Band
61%Mid-range
SMA Cross
Death CrossDeath Cross
Trend Quality (KER)
0.190Noisy/choppy

FUNDAMENTALS

66/100
EV/EBIT
15.1Fair
P/FCF
17.9Fair
P/S
2.1Fair
Shareholder Yield
1.9%Low

Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months47
3-12 months ★85
1-5+ years60

6-9 month momentum thesis — strong trend with confirmation

BRAIN47'S ASSESSMENT

I rate Dermapharm Holding SE at 64/100 — a STRONG reading on the Brain47 Signal. The strongest factor is momentum at 88/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.

PAST PERFORMANCE

1 MONTH

+6.3%

3 MONTHS

+21.3%

12 MONTHS

+41.9%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

6-9 month momentum thesis — strong trend with confirmation. Momentum (88) and Fundamentals (66) are the primary strengths. Historical volatility is moderate at 39%. I classify this as a growth position — strong momentum combined with solid fundamentals points to capital appreciation.

growthScore: 64/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.